Total Funding
47
56
Total FundingPost-IPO Equity raised
Growth Score
-33 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
85717
Avadel Pharmaceuticals is a biopharmaceutical company that develops and delivers medications, with a focus on narcolepsy treatment.
- Douglas Williamson: Chief Medical Officer
- Thomas S . McHugh: Chief Financial OfficerPast Role: Lumara Health, CFO
Alkermes
About the Company
Avadel Pharmaceuticals is a biopharmaceutical company dedicated to developing modified medications that address patient challenges with existing treatment options. The company's primary focus is on narcolepsy, for which its commercial product is LUMRYZ (sodium oxybate for extended-release oral suspension). LUMRYZ is notable for its
once-at-bedtime dosing regimen for treating cataplexy or excessive daytime sleepiness in patients with narcolepsy.
